Abbott Laboratories reported a 7.4% increase in sales for the second quarter of 2025, amounting to $11.142 billion. The company achieved a GAAP diluted earnings per share (EPS) of $1.01 and an adjusted diluted EPS of $1.26, reflecting double-digit growth compared to the previous year. Notably, the gross margin improved to 52.7%, with an adjusted gross margin of 57.0%, marking a 100 basis point increase. The growth in sales was driven by strong performance in its Medical Devices and Established Pharmaceuticals segments, while Diagnostics sales experienced a decline due to reduced COVID-19 testing-related revenue.
For the first half of 2025, Abbott reported a 5.7% increase in sales, with projections for the full year indicating organic sales growth of 7.5% to 8.0%, excluding COVID-19 testing-related sales. The company also announced plans to develop a new cardiovascular device manufacturing facility in Georgia, expected to be completed by 2028. Abbott declared its 406th consecutive quarterly dividend of $0.59 per share, payable on August 15, 2025, to shareholders of record by July 15, 2025.
linkJul 17, 2025 07:34:53
Abbott reported a first-quarter GAAP diluted earnings per share (EPS) of $0.76 and an adjusted diluted EPS of $1.09, reflecting a growth of 11.2% compared to the previous year. The company experienced a 4.0% increase in reported sales and a 6.9% organic sales growth, which rose to 8.3% when excluding COVID-19 testing-related sales. The gross margin also improved, with an adjusted gross margin of 57.1%, showing a 140 basis point increase. Abbott reaffirmed its full-year financial guidance and highlighted recent advancements in its medical technology, including the CE Mark for its Volt™ PFA System and the initiation of a pivotal trial for its Coronary Intravascular Lithotripsy System in the U.S.
Conversely, Abbott's Diagnostics segment faced challenges with a reported sales decline of 7.2% and an organic decrease of 4.9%, largely due to reduced COVID-19 testing-related sales. The company noted that COVID-19 testing sales dropped to $84 million from $204 million in the prior year. Additionally, established pharmaceuticals sales grew only 2.7% on a reported basis, indicating slower performance in that area. The international markets also showed mixed results, with some segments experiencing declines attributed to foreign exchange impacts and volume-based procurement programs in China.
linkApr 16, 2025 07:36:02
Abbott's fourth-quarter sales reached $11.0 billion, marking a 7.2% increase from the previous year, with organic sales growth at 10.1% when excluding COVID-19 testing. The company also reported a full-year 2024 sales total of $42.0 billion, up 4.6% from 2023, and achieved the upper end of its guidance for organic sales growth and adjusted earnings per share. The gross margin improved, and Abbott announced over 15 new growth opportunities from its R&D pipeline throughout the year.
However, Abbott faced challenges in its Diagnostics segment, with sales affected by declines in COVID-19 testing-related revenue, which dropped to $176 million in the fourth quarter from $288 million the previous year. Additionally, the company discontinued the ZonePerfect product line in its Nutrition business, impacting sales figures. Despite these setbacks, Abbott projects continued organic sales growth for 2025 in the range of 7.5% to 8.5%.
linkJan 22, 2025 07:13:21
Abbott's third-quarter results for 2024 show a solid performance with total sales reaching $10.6 billion, marking a 4.9% increase compared to the previous year. The company reported impressive organic sales growth of 8.2%, primarily driven by strong demand in the Medical Devices segment, which saw double-digit growth. Additionally, Abbott has raised its full-year earnings guidance, reflecting confidence in its ongoing business strategies and product innovations, including recent partnerships and new product launches aimed at enhancing healthcare solutions.
Despite some challenges in the Diagnostics sector, particularly due to declining COVID-19 testing sales, Abbott's overall diversified business model remains strong. The company also announced a significant $7 billion share repurchase program and continues to uphold its long-standing tradition of increasing dividends, having done so for 52 consecutive years. These factors contribute to a positive outlook for Abbott, indicating robust operational health and commitment to shareholder returns.
linkOct 16, 2024 07:37:36
Abbott's Q2 2024 results show $10.4 billion in sales with a 4% growth, led by a 9.3% organic sales increase in Medical Devices. The company raised its full-year EPS guidance. They introduced innovative products like Esprit™ BTK system and obtained FDA clearance for glucose monitoring systems. Abbott's CEO highlighted positive momentum and growth opportunities from R&D. Nutrition and Diagnostics segments saw organic growth. However, Diagnostics sales were impacted by lower COVID-19 testing demand. Overall, Abbott reported a robust performance and optimistic outlook for the future.
linkJul 18, 2024 07:37:35
Abbott's Q1 2024 results show $10.0 billion in sales, with strong organic growth of 10.8%. The company raised its full-year EPS guidance, expecting $3.25 to $3.40 on a GAAP basis and $4.55 to $4.70 adjusted. New product launches and FDA approvals enhance Abbott's offerings. Despite a decline in COVID-19 testing-related sales, the company's overall performance is positive, with consecutive quarters of double-digit organic sales growth.
linkApr 17, 2024 07:36:02
Abbott Laboratories entered into a Five Year Revolving Credit Agreement, providing the ability to borrow up to $5 billion on an unsecured basis, with no outstanding borrowings at present. The agreement includes flexible interest rates and customary fees. The company also terminated its previous credit agreement, which had a similar borrowing capacity and terms. Both agreements involve services from JPMorgan Chase Bank and affiliates.
linkJan 29, 2024 16:10:51
Abbott's Q4 sales increased 1.5%, with organic growth at 11.0%. Full-year 2023 sales decreased 8.1% due to COVID-19 testing decline, but organic growth was 11.6%. The company issued positive 2024 financial outlook and highlighted successful product launches, FDA approvals, and market share recapture. The CEO expressed optimism for 2024 and beyond, emphasizing a strong pipeline and market position.
linkJan 24, 2024 07:36:44
Abbott reported sales of $10.1 billion in Q3 2023, driven by strong underlying base business performance, with organic sales growth of 13.8 percent. The company raised its full-year EPS guidance range and continues to project double-digit organic sales growth for the year. Abbott also highlighted key developments, including obtaining CE Mark for its AVEIR single-chamber leadless pacemaker, acquiring Bigfoot Biomedical, and expanding its collaboration with mAbxience Holdings. The company's CEO expressed confidence in meeting financial commitments and building momentum for 2024.
linkOct 18, 2023 07:37:08